Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

PEOPLE - Sequana Therapeutics makes appointment:

This article was originally published in Clinica

  • News

Executive Summary

US genomics company Sequana Therapeutics has promoted Steve Sugino to vice-president of corporate development.

You may also be interested in...



Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.

Swisse Supplements Take Bigger Slice Of Chinese Market

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

Novartis Draws Out Its APPLAUSE

China VBP, Localization And Other Strategies - How Far And Which Way?

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

See All
UsernamePublicRestriction

Register

MT086647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By